Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

Ca-A Cancer Journal for Clinicians · Published 2026-03-01 · DOI 10.3322/caac.70072

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.3322/caac.70072

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics · Ca-A Cancer Journal for Clinicians · 2026 · Same journal
• CA turns 75: Looking at the future but never forgetting the roots · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• Regorafenib as maintenance therapy showed significant delayed progression of non‐adipocytic soft tissue sarcomas · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study · Ca-A Cancer Journal for Clinicians · 2026 · Same journal
• Human papillomavirus self‐collection: The long road from scientific evaluation to implementation in screening programs · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma · Ca-A Cancer Journal for Clinicians · 2026 · Same journal
• Cancer treatment and survivorship statistics, 2025 · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• Frailty in patients undergoing cancer treatment linked to significantly more adverse outcomes · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future · Ca-A Cancer Journal for Clinicians · 2025 · Same journal
• PORTEC‐3 trial finds that adjuvant chemoradiotherapy significantly improves 10‐year survival for patients with high‐risk endometrial cancer · Ca-A Cancer Journal for Clinicians · 2026 · Same journal